BDBM296547 6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methoxybenzyl)- 3,6- diazabicyclo[3.1.1] heptan-3- yl)pyridin-3- yl)pyrazolo[1,5- a]pyridine-3- carbonitrile::US10112942, Example 281::US10137124, Example 281::US10172851, Example 281::US10555944, Example 281::US10953005, Example 281

SMILES COc1ccc(CN2C3CC2CN(C3)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cc1

InChI Key InChIKey=LNVAQIQIPFWXNF-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 296547   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  9.40nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  19.3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  9.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  19.3nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  9.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  9.40nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296547(6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-(4- methox...)
Affinity DataIC50:  9.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent